Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Emergent BioSolutions (NYSE: EBS) has announced two upcoming investor events. The company will host a conference call on March 3, 2025, at 5:00 pm ET to discuss fourth quarter and full year 2024 financial results. Additionally, company leaders will present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025, at 11:00 am ET.
Both events will be accessible via webcast through the company's Investors page. For the earnings call, telephone participants must register in advance to receive dial-in details and access credentials. A replay of the earnings call will be available on Emergent's website.
Emergent BioSolutions (NYSE: EBS) ha annunciato due eventi per investitori in programma. L'azienda ospiterà una conference call il 3 marzo 2025, alle 17:00 ET per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024. Inoltre, i leader dell'azienda presenteranno alla J.P. Morgan's 2025 Leveraged Finance Conference il 24 febbraio 2025, alle 11:00 ET.
Entrambi gli eventi saranno accessibili tramite webcast attraverso la pagina Investitori dell'azienda. Per la conference call sugli utili, i partecipanti telefonici devono registrarsi in anticipo per ricevere i dettagli di accesso e le credenziali. Una registrazione della conference call sugli utili sarà disponibile sul sito web di Emergent.
Emergent BioSolutions (NYSE: EBS) ha anunciado dos próximos eventos para inversores. La compañía llevará a cabo una llamada de conferencia el 3 de marzo de 2025, a las 5:00 pm ET para discutir los resultados financieros del cuarto trimestre y del año completo 2024. Además, los líderes de la empresa presentarán en la J.P. Morgan's 2025 Leveraged Finance Conference el 24 de febrero de 2025, a las 11:00 am ET.
Ambos eventos serán accesibles a través de una transmisión web en la página de Inversores de la compañía. Para la llamada de ganancias, los participantes por teléfono deben registrarse con anticipación para recibir los detalles de acceso y credenciales. Una grabación de la llamada de ganancias estará disponible en el sitio web de Emergent.
Emergent BioSolutions (NYSE: EBS)는 두 개의 투자자 이벤트를 발표했습니다. 회사는 2025년 3월 3일 오후 5시 ET에 2024년 4분기 및 연간 재무 결과에 대해 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다. 또한 회사 리더들은 J.P. Morgan's 2025 Leveraged Finance Conference에서 2025년 2월 24일 오전 11시에 발표할 것입니다.
두 이벤트 모두 회사의 투자자 페이지를 통해 웹캐스트로 접근할 수 있습니다. 실적 발표 전화회의에 참여하는 경우, 전화 참가자는 사전에 등록하여 다이얼인 세부정보 및 접근 자격을 받아야 합니다. 실적 발표의 재생은 Emergent 웹사이트에서 제공될 것입니다.
Emergent BioSolutions (NYSE: EBS) a annoncé deux événements à venir pour les investisseurs. La société organisera une conférence téléphonique le 3 mars 2025 à 17h00 ET pour discuter des résultats financiers du quatrième trimestre et de l'année complète 2024. De plus, les dirigeants de l'entreprise présenteront à la J.P. Morgan's 2025 Leveraged Finance Conference le 24 février 2025, à 11h00 ET.
Les deux événements seront accessibles par webdiffusion via la page Investisseurs de la société. Pour l'appel de résultats, les participants par téléphone doivent s'inscrire à l'avance pour recevoir les détails d'accès et les identifiants. Un enregistrement de l'appel de résultats sera disponible sur le site web d'Emergent.
Emergent BioSolutions (NYSE: EBS) hat zwei bevorstehende Investorenveranstaltungen angekündigt. Das Unternehmen wird am 3. März 2025 um 17:00 Uhr ET eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse des vierten Quartals und des gesamten Jahres 2024 zu besprechen. Darüber hinaus werden Unternehmensleiter am J.P. Morgan's 2025 Leveraged Finance Conference am 24. Februar 2025 um 11:00 Uhr ET präsentieren.
Beide Veranstaltungen sind über einen Webcast auf der Investoren-Seite des Unternehmens zugänglich. Für den Gewinnaufruf müssen Telefonteilnehmer sich im Voraus registrieren, um die Einwahldaten und Zugangsdaten zu erhalten. Eine Wiederholung des Gewinnaufrufs wird auf der Website von Emergent verfügbar sein.
- None.
- None.
Separately, Company leaders will attend and present at J.P. Morgan’s 2025 Leveraged Finance Conference on February 24, 2025
GAITHERSBURG, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, March 3, 2025, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2024.
Participants can access the conference call live via webcast, and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
Additional Investor Event – Webcast Information
Emergent will also provide a brief presentation and remarks during J.P. Morgan’s 2025 Leveraged Finance Conference. Participants may access the presentation via webcast at 11:00 am eastern time on Monday, February 24, 2025.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For over 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
When will Emergent BioSolutions (EBS) report Q4 and full year 2024 earnings?
How can investors access EBS's Q4 2024 earnings call?
When is Emergent BioSolutions (EBS) presenting at the J.P. Morgan Leveraged Finance Conference?
Will there be a replay available for EBS's Q4 2024 earnings call?
